Skip to main content
IDWeek 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
Live Streamed
On Demand
On Demand
Back

Charles L. Daley, MD (he/him/his)

Chief, Division of Mycobacterial & Respiratory Infections  Professor, Medicine 
National Jewish Health
Denver , CO, United States

Charles L. Daley, MD, is the chief of the Division of Mycobacterial and Respiratory Infections at National Jewish Health (NJH) in Denver, CO and a professor of medicine at NJH, the University of Colorado, and Icahn School of Medicine at Mount Sinai. He received his medical degree from the University of Mississippi School of Medicine. He then went on to complete his residency in internal medicine and fellowship in pulmonary disease and critical care medicine at the University of California, San Francisco.

Dr Daley’s academic interests include tuberculosis (TB) global health policy and clinical and translational research related to TB and nontuberculous mycobacteria (NTM) infections. He has served on and chaired expert panels for the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Infectious Diseases Society of America, and the American Thoracic Society. He has participated on multiple guideline panels for these organizations, including guidelines that address diagnosis, treatment (drug-susceptible and drug resistant) and prevention of tuberculosis. Dr Daley chaired the revision of the multi-society sponsored NTM Treatment Guideline. For his work in global TB control, he was awarded the World Lung Health Award by the American Thoracic Society. Dr Daley was previously an Associate Editor of the American Journal of Respiratory and Critical Care Medicine and European Respiratory Journal.

Disclosure(s): AN2 Therapeutics, Inc.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Bill & Melinda Gates Foundation: Advisor/Consultant (Ongoing); Bugworks Research, Inc.: Grant/Research Support (Terminated, June 30, 2024); Galapagos NV: Advisor/Consultant (Ongoing); Genentech: Advisor/Consultant (Ongoing); Hyfe: Advisor/Consultant (Ongoing); Insmed Inc: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Juvabis: Grant/Research Support (Ongoing); MannKind: Advisor/Consultant (Ongoing); Matinas Biopharma,: Advisor/Consultant (Ongoing); NobHill Therapeutics: Advisor/Consultant (Ongoing); Otsuka Pharmaceuticals: Advisor/Consultant (Terminated, July 31, 2024); Paratek Pharmaceuticals: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer, Inc.: Advisor/Consultant (Ongoing); Spero Therapeutics,: Advisor/Consultant (Ongoing); Zambon: Advisor/Consultant (Ongoing)

Presentation(s):